OmniComm Systems, a provider of electronic data capture, announced an $8-10 million deal with an unnamed firm. It appears to be a major win for the Florida company. “We are very excited to be chosen by such a prestigious company to manage their clinical trials over the next 5 years,” said Stephen Johnson, OmniComm’s chief operating officer. Here’s the release.

Cytel hired Judith Quinlan as VP of adaptive trials. “Judith Quinlan has been a persistent and persuasive proponent of adaptive clinical trials both at GSK, and through her work with the PhRMA Working Group on Adaptive Designs (ADWG). This is helping pave the way toward the wide acceptance of innovative, flexible clinical study approaches,” said Cytel’s CEO, Ranganath Nayak. Here’s the release.

Global Business Insights, based in the UK, has a new $3,835 report on adaptive designs by Cheryl Barton. This is the table of contents.

Forbes is asking whether Schering’s Fred Hassan, a highly regarded exec, should forfeit his $13 million bonus over the Vytorin saga, in which clinical trial endpoints were changed, and scientific publication delayed, for a disputed interval of time. This might be an interesting topic for parlor debate if any CEO compensation were correlated to performance in any industry.

Bio-Imaging, specializing in clinical trial imaging and electronic data capture, will participate in the interoperability project surrounding electronic health records. The company is attending a medical records convention this week. “By integrating with AllOne Mobile and participating in their demonstration, we will show attendees how we empower the consumer to become their own health advocates,” said Mary Ellen Zipper, director of client relations for CapMed, a division of Bio-Imaging. Here’s the release.

Google Health went live. It’s well designed—and creepy. The site features an easy way for individuals to upload their medical records, which includes a way to record brand-name prescription drug usage. Only nitwits will rush to upload actual medical records to the website. But, America being America, that could amount to more than a few people. “When you provide your information through Google Health, you give Google a license to use and distribute it in connection with Google Health and other Google services,” the company’s guidelines say. Translation: we’re going to sell your information to anyone with a pulse. (ClinPage typed in a long list of medications we’re not taking, just to see what alerts and privacy violations we can trigger.) The search advertising goliath is not covered by the main U.S. privacy law around health information, its lawyers gloat: “HIPAA does not apply to the transmission of health information by Google to any third party.” Once Google’s data partners have your most sensitive information, by the way, there’s no getting it back. We like the company. Who doesn’t? But its benevolence and business acumen are exaggerated.

Have a news release? Send it to .